Stock market
臨床申請差し戻し、技術移転は音沙汰なし…韓国バイオ株乱高下
韓国のバイオ株が乱高下している。海外企業と薬物送達技術を検証する契約を結び、株価が急騰する企業がある一方、技術輸出への期待に冷や水を浴びせるニュースも伝わっている。その過程で株価がジェットコースターのように動き、投資家のため息も深まっている。◇海外契約、臨床の変数に揺れるKバイオ OliXとPeptronは今月、株価が大きく揺れた。OliXはニュージーラン
Related discussion groups
No group discusses this yet. Start a discussion group and attach this story.
More on Stock market
- Big Oil Eyes Record Profits but Keeps Spending in CheckOil supermajors have been raking it in since the war in the Middle East began. They are now set to report another robust quarter, even as some jurisdictions where they operate plan to slap windfall...
- Broad support for populist policies found across party lines in Wall Street Journal pollPolarization exists between the two parties, but according to a survey conducted by The Wall Street Journal, many populist policies are finding broad support across party lines. Pollsters John Anza...
- Meta reportó ingresos de 64.601 millones de dólares en el tercer trimestre de 2026 y subió en Wall StreetLa compañía reportó ganancias por acción de 3,83 dólares, por encima de la estimación de consenso de 3,57 dólares
- US Stock Futures Slip as Tech Earnings Rally Fades: Markets WrapUS equity-index futures fell as a technology rally faded, trimming gains sparked by strong earnings that had bolstered confidence in the artificial intelligence trade.
- Stocks rise on AI-led earnings, France's 10-year bond yield hits 5%
- „Nu am cunoștință ca noi să fi știut”. Rubio, despre cine a luat decizia limitării unei tehnologii-cheie utilizate pe frontul din UcrainaȘeful diplomației americane, Marco Rubio, a declarat miercuri că deciziile privind accesul Ucrainei la rețeaua Starlink revin companiei-mamă SpaceX și lui Elon Musk, nu Casei Albe, informează Reute...